We achieved an increase in pregnancy rates in poor responders with the administration of GnRH antagonists, according to our recent publication which is the world's largest study of its kind.

In our study, with the world's largest cohort of poor responders, the flexible GnRH antagonist protocol has proven to lead in a significant increase of ongoing pregnancy rates when compared with the short GnRH agonist protocol (Lainas et al., 2008).

We achieved a significant reduction in the development of severe hyperstimulation syndrome (OHSS) in women with polycystic ovaries, according to our recent publication, which is the world's largest study of its kind.

In addition, in a recent publication which is the world's largest in regard with the number of patients with polycystic ovarian syndrome (PCOS), we showed that the use of a flexible GnRH antagonist protocol leads to a statistically significant reduction in the development of severe ovarian hyperstimulation syndrome (OHSS) by 20%, when compared with the long protocol, without simultaneous reduction of pregnancy rates (Lainas et al., 2010).

Selection of our study amongst ten others in the editorial of Professor Andre Van Steirteghem, editor of the scientific journal of Human Reproduction, with regards to the optimum ovarian stimulation protocol in women with polycystic ovarian syndrome that underwent assisted reproduction treatment.

See the report of Professor Andre Van Steirteghem in the article titled Editor's choice Human Reproduction, 2010, Vol.25, No.3 p. 561.

The international scientific organisation FACULTY OF 1000 MEDICINE that reviews and evaluates published clinical studies with significant scientific findings that can change our current clinical practice, evaluated our recently published study titled:

«Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective RCT»
Trifon G Lainas, Ioannis A Sfontouris, Ioannis Z Zorzovilis, George K Petsas, George T Lainas, Efthymia Alexopoulou, Efstratios M Kolibianakis
Human Reproduction, 2010, Vol 25, No.3 pp.683-689.

The two independent reviewers that evaluated our study conclude that: "it is by far the single largest randomized controlled trial performed internationally" and the new antagonists protocol can be proposed as a protocol of choice for women with polycystic ovaries.

The new protocol is more safe and effective than the traditional long protocol, since it presents a statistically reduced chance of severe ovarian hyperstimulation syndrome, a smaller total dose of gonadotrophins and a shorter duration of ovarian stimulation, whilst maintaining the same high pregnancy rates.

See the study

See the report regarding our study by FACULTY OF 1000 MEDICINE

Eugonia was represented by Dr Trifon Lainas, Dr Ioannis Zorzovilis, and Dr Ioannis Sfontouris, at the Annual Conference of the European Society of Human Reproduction and Embryology (ESHRE) that took place in Stockholm on 3-6 July 2011. We actively participated in the scientific program of the conference by presenting our latest results from the use of the novel method of embryo assessment metabolomics. Our study was distinguished by the scientific committee of the Conference and was nominated for the Fertility Society of Australia Exchange Award.

In "Εugonia", the pregnancy success rate after cultivation and blastocyst  transfer for the years 2010-2011 reached an impressive 88% per embryotransfer in women under the age of 35. The pregnancy percentage is equally high (72 %)  for ages at 35 to 39 years, while the "difficult" group of women over 40 years, the pregnancy possibility reaches 56 %.

These impressive percentages reflect the embryologic modern lab, the ideal growing conditions and the best pharmaceutical protocols to be applied to "Εugonia".

We released the largest literature study for the severe ovarian hyperstimulation syndrome treatment (OHSS) at the international scientific journal Reproductive Biology and Endocrinology. This is a prospective observational study (observational cohort study) of 362 high risk for serious OHSS appearance women . The 11.3 % of women have experienced serious OHSS which was successfully dropped just a few days after the grant luteal GnRH competitor stage.

See the publication here http://www.ncbi.nlm.nih.gov/pubmed/22938051

The Eugonia scientific team, headed by Dr Τrifonas Lainas, in collaboration with the Clinical genetic laboratory University of Athens, led to achieve pregnancy patient who suffered from the neurofibromatosis disease (neurofibromatosis type 1, also known as von Recklinghausen disease).

Neurofibromatosis is a genetic neurological disease caused by mutation, which has a 50% potential to be transferred to children in case that one of the 2 parents is suffering from it, while the disease severity varies from person to person.

The application for in-vitro fertilisation in conjunction with preimplantation genetic diagnosis (SGA), successfully detected the healthy embryos, which were transferred to a woman's uterus , while embryos which suffered the disease were excluded. Pregnancy outcome was successfull, and the woman gave birth to a healthy baby girl.

"Εugonia" group, in cooperation with the company MSD, successfully organized a symposium entitled "advances in assisted reproduction', in Heraklion Crete on October 12, 2012. Various protocols of ovarian stimulation were discussed , with emphasis on a new drug injection use (Corifollitropin), as well as the quality criteria for assisted reproduction units.

Dr Τrifon Lainas and Dr Ioannis Ζorzovilis participated in the European Company human reproduction and embryology (ESHRE) annual conference, which took place in Istanbul on July 2-4, 2012, where they were informed of the latest developments in the field of assisted reproduction.